LCTB-21: A DYRK1A protein kinase inhibitor for treatment of cognitive decline in Down Syndrome.

Project Information

DOWN-AUTONOMY

Grant agreement ID: 190138295

DOI

10.3030/190138295

EC signature date 16 November 2022

Start date 1 June 2022

End date 30 June 2026

Funded under

• The European Innovation Council (EIC)

Total cost

€ 11 359 709,00

EU contribution

€ 2 500 000,00

Coordinated by

PERHA PHARMACEUTICALS SAS
France

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Deliverables

Websites, patent fillings, videos etc. (1)

Communication to the scientific community and the general public 1

Communication to the scientific community and the general public

Publications

Peer reviewed articles (3)

Leucettinibs, a class of DYRK/CLK kinases inhibitors inspired by the marine sponge natural product Leucettamine B

Author(s): Deau E., Lindberg, M.F., Miège, F., Roche, D., George, N., George, P., Berger, B.-T., Krämer A., Knapp S. and Meijer, L.
Published in: J. Med. Chem., 2023, ISSN 0022-2623
Publisher: American Chemical Society
DOI: 10.1021/acs.jmedchem.3c00884

Comparative efficacy and selectivity of pharmacological inhibitors of DYRK and CLK protein kinases

Author(s): Lindberg, M.F., Deau, E., Arfwedson, J., George, N., George, P., Alfonso, P. and Meijer, L.
Published in: J. Med. Chem., 2023, ISSN 0022-2623
Publisher: American Chemical Society
DOI: 10.1021/acs.jmedchem.2c02068

Chemical, biochemical, cellular, and physiological characterization of Leucettinib-21, a Down syndrome and Alzheimer’s disease drug candidate

Author(s): Lindberg, M.F., Deau, E., Miège, F., Gréverie, M., Roche, D., George, N., George, P., Merlet, L., Gavard, J., Brugman, S.J.T., Aret, E., Tinnemans, P., De Gelder, R., Sadownik, J., Verhofstad, E., Sleegers, D., Santangelo, S., Dairou, J., Fernandez, A., D
Published in: J. Med. Chem., 2023, ISSN 0022-2623
Publisher: American Chemical Society
DOI: 10.1021/acs.jmedchem.3c01888